Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Q34655572)

3 August 2017

title

Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

ESMO Guidelines Working Group

3 August 2017

1 reference

series ordinal

3

object named as

ESMO Guidelines Working Group

1 reference

3 August 2017

M F Fey

1

1 reference

3 August 2017

C Buske

series ordinal

2

1 reference

3 August 2017

publication date

22 August 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

24 Suppl 6

1 reference

3 August 2017

page(s)

vi138-43

1 reference

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Molecular markers in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Current treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Acute myeloid leukemia in first remission: to choose transplantation or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Acute myeloid leukemia and the position of autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaem

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Modern approaches to treating acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT320

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT320

1 reference

3 August 2017

1 reference